

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | | |
|--|---|
| 1. | Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
| No additional equality issues were raised during the second or third committee meetings. | |

- | | |
|----|---|
| 2. | If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No | |

- | | |
|----|--|
| 3. | If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No | |

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
N/A	

5.	Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes, see section 3.25.	

Approved by Associate Director: Emily Crowe

Date: 10/12/2025